Platinum (IV) compounds targeting zinc finger domains

• US 8,895,610 B1
• Filed: 01/21/2011
• Issued: 11/25/2014
• Est. Priority Date: 05/18/2007
• Status: Active Grant

• Current Assignee: Heldi Kay
• Original Assignee: Heldi Kay
• Inventors: Kay, Heldi
• Primary Examiner(s): Peselev, Elli
• Application Number:
  US13/011,613
• Time in Patent Office: 1,404 Days
• Field of Search: 514/492
• US Class Current: 514/492
• CPC Class Codes: A61K 31/282 Platinum compounds
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

This application pertains to compositions and use of platinum(IV) compounds to alter zinc-binding sites, zinc-binding domains, zinc metalloproteins or zinc-associated proteins. Such interactions alter specific activities of these zinc-binding sites and associated protein functions, therefore offering therapeutic value.

Claims

1. A method of treating an infection of a viral pathogen in a subject, the method comprising:

administering a platinum (IV) complex effective for treating an infection of a viral pathogen to the subject, the platinum IV complex comprising the structure shown in at

2. The method of claim 1 wherein the viral pathogen is a Picornaviridae, poliovirus, human coxsackievirus, hepatitis A virus, Flaviviridae, yellow fever virus, Dengue virus, West Nile virus, Kunjin virus, St. Louis encephalitis virus, hepatitis C virus), Togaviridae rubella virus, Coronaviridae, human coronavirus, human SARS-associated coronavirus, Rhabdoviridae, rabies virus, Paramyxoviridae, human parainfluenza virus, measles virus, human respiratory syncytial virus, Filoviridae, Marburg virus, Ebola virus, Bornaviridae, Borna disease virus, Bunyaviridae, Hantaan virus, Arenaviridae, Lassa virus, Junin virus, Tacaribe virus, Reoviridae human rotavirus, Herpesviridae, HSV-1, HSV-2, Epstein-Barr Virus, Retroviridae, HIV-1, SIV, SHIV, FIV, HTLV-1, MTLV, MMTV, or HIV-2.